ArticleScientific reports2025
First trimester hepatic steatosis index as a predictor of gestational diabetes mellitus: a cohort study in Northwestern China.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Perinatal Semaglutide Treatment Improves Maternal Health and Mitigates Offspring Metabolic Dysfunction in a Mouse Model of Maternal Obesity.bioRxiv : the preprint server for biology · 2026Article
- Early-pregnancy BMI-derived adiposity change rate and gestational diabetes mellitus risk: modification by a fatty liver index-defined hepatic-metabolic phenotype.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
To investigate the predictive value of the hepatic steatosis index (HSI) in the first trimester for gestational diabetes mellitus (GDM), and explore the association between HSI and the risk of developing GDM. A total of 2795 pregnant women were included in this cohort study. Maternal baseline data and basic laboratory data, including alanine aminotransferase, aspartate aminotransferase, fasting plasma glucose (FPG), and others were collected during 8-13 weeks of gestation. The 75-g oral glucose tolerance test was conducted at 24-28 weeks of gestation, and according to the criteria of American Diabetes Association, the participant would be diagnosed as GDM if one of the thresholds was met: fasting blood glucose ≥ 5.1 mmol/L, 1-h blood glucose ≥ 10.0 mmol/L, or 2-h blood glucose ≥ 8.5 mmol/L. The relationship between first-trimester HSI and GDM outcomes was analyzed by using Logistic Regression, Restricted Cubic Spline and Subgroup Analyses. The nomogram model including HSI, FPG and other factors was established, and diagnostic efficacies of the nomogram model, FPG, HSI, and white blood cell count (WBC) were analysed by using the receiver operating characteristic curve. 212 pregnant women were diagnosed with GDM among 2,795.After adjusting for the covariates, compared to women in the lowest quartile (Q1), those in the highest quartile group (Q4) of first-trimester HSI had a 2.328-fold risk of developing GDM (95% CI 1.262-4.295, p < 0.05). There was a positive nonlinear dose-response relationship between the first-trimester HSI and GDM (p for overall < 0.001; p for nonlinear = 0.010). Subgroup analyses found that HSI didn't interact with covariates such as age, gravidity, parity, etc. (p > 0.05). The diagnose efficacies of the nomogram model, HSI, FPG and WBC were 0.737 (95% CI 0.702-0.773), 0.696 (95% CI 0.658-0.734), 0.631 (95% CI 0.593-0.670), and 0.569 (95% CI 0.526-0.611), respectively. First-trimester HSI, FPG, WBC, and age may jointly predict the occurrence of GDM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.